Literature DB >> 11023098

Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct.

B Terris1, P Ponsot, F Paye, P Hammel, A Sauvanet, G Molas, P Bernades, J Belghiti, P Ruszniewski, J F Fléjou.   

Abstract

Intraductal papillary mucinous tumors (IPMTs) of the pancreas are rare tumors characterized by a malignant potential. Because of the progress of imaging procedures, smaller cystic pancreatic lesions are now detected and some of them correspond to IPMTs that involve ectatic pancreatic branch ducts but spare the main pancreatic duct. To investigate differences in morphology and clinical behavior of branch and main duct types of IPMT, a surgical series of 43 cases was studied. All pathologic specimens of IPMT, surgically resected in our institution between October 1987 and July 1998, were analyzed. In all cases, the entire pancreatic specimen was systematically examined. IPMT of the branch type was found in 13 (30%) patients, whereas IPMT of main pancreatic duct type that involved the main pancreatic duct and branch ducts was observed in 30 (70%) patients. Patients with IPMT of the branch type were younger (median age, 55 yrs vs 64 yrs), and all but one of the lesions were located in the head and neck of the pancreas (vs 17 of 30 patients with the main duct type). The size of the cysts ranged from 4 to 55 mm, and the major duct showed a mild dilation in most cases. In contrast to the main pancreatic duct type, which showed invasive carcinoma and in situ carcinoma in 11 (37%) of 30 patients and 6 (20%) of 30 patients, respectively, IPMT of the branch type showed significantly less aggressive histologic lesions with five (39%) patients with simple hyperplasia, six (46%) patients with atypical hyperplasia, and two (15%) patients with in situ carcinoma. No invasive carcinoma was observed in this group. IPMT of the branch type occurs in younger patients and is associated with less aggressive histologic features than is the main pancreatic duct type. Our findings raise the difficult issue of clinical management of IPMT of the branch type as a distinctive group.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11023098     DOI: 10.1097/00000478-200010000-00006

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  90 in total

1.  Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Hanno Matthaei; Alexis L Norris; Athanasios C Tsiatis; Kelly Olino; Seung-Mo Hong; Marco dal Molin; Michael G Goggins; Marcia Canto; Karen M Horton; Keith D Jackson; Paola Capelli; Giuseppe Zamboni; Laura Bortesi; Toru Furukawa; Shinichi Egawa; Masaharu Ishida; Shigeru Ottomo; Michiaki Unno; Fuyuhiko Motoi; Christopher L Wolfgang; Barish H Edil; John L Cameron; James R Eshleman; Richard D Schulick; Anirban Maitra; Ralph H Hruban
Journal:  Ann Surg       Date:  2012-02       Impact factor: 12.969

2.  Surgical treatment of intraductal papillary mucinous neoplasms of the pancreas: the conservative approach.

Authors:  Carlos Fernandez-del Castillo
Journal:  J Gastrointest Surg       Date:  2002 Sep-Oct       Impact factor: 3.452

Review 3.  Primary cystic neoplasms of the pancreas. Neoplastic disorders of emerging importance-current state-of-the-art and unanswered questions.

Authors:  Michael G Sarr; Michel Murr; Thomas C Smyrk; Charles J Yeo; Carlos Fernandez-del-Castillo; Robert H Hawes; Patrick C Freeny
Journal:  J Gastrointest Surg       Date:  2003 Mar-Apr       Impact factor: 3.452

4.  A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas.

Authors:  Olca Basturk; Seung-Mo Hong; Laura D Wood; N Volkan Adsay; Jorge Albores-Saavedra; Andrew V Biankin; Lodewijk A A Brosens; Noriyoshi Fukushima; Michael Goggins; Ralph H Hruban; Yo Kato; David S Klimstra; Günter Klöppel; Alyssa Krasinskas; Daniel S Longnecker; Hanno Matthaei; G Johan A Offerhaus; Michio Shimizu; Kyoichi Takaori; Benoit Terris; Shinichi Yachida; Irene Esposito; Toru Furukawa
Journal:  Am J Surg Pathol       Date:  2015-12       Impact factor: 6.394

Review 5.  Intraductal papillary mucinous neoplasms of the pancreas: making a disposition using the natural history.

Authors:  L William Traverso; Toshiyuki Moriya; Yasushi Hashimoto
Journal:  Curr Gastroenterol Rep       Date:  2012-04

6.  Multicentric invasive carcinomas derived from intraductal papillary mucinous neoplasm (IPMN) of the pancreas: report of a case.

Authors:  Yoshihisa Naitoh; Shinichi Ban; Chouji Tsuchiya; Yoshiaki Sugiura; Michio Shimizu
Journal:  Virchows Arch       Date:  2007-02-28       Impact factor: 4.064

7.  Frozen sectioning of the pancreatic cut surface during resection of intraductal papillary mucinous neoplasms of the pancreas is useful and reliable: a prospective evaluation.

Authors:  Anne Couvelard; Alain Sauvanet; Reza Kianmanesh; Pascal Hammel; Nathalie Colnot; Philippe Lévy; Philippe Ruszniewski; Pierre Bedossa; Jacques Belghiti
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

8.  Natural History of Patients Followed Radiographically with Mucinous Cysts of the Pancreas.

Authors:  Linda M Pak; Michael I D'Angelica; Ronald P DeMatteo; T Peter Kingham; Vinod P Balachandran; William R Jarnagin; Peter J Allen
Journal:  J Gastrointest Surg       Date:  2017-05-17       Impact factor: 3.452

Review 9.  Precursors to pancreatic cancer.

Authors:  Ralph H Hruban; Anirban Maitra; Scott E Kern; Michael Goggins
Journal:  Gastroenterol Clin North Am       Date:  2007-12       Impact factor: 3.806

10.  Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection.

Authors:  Roberto Salvia; Carlos Fernández-del Castillo; Claudio Bassi; Sarah P Thayer; Massimo Falconi; William Mantovani; Paolo Pederzoli; Andrew L Warshaw
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.